Page last updated: 2024-12-10
geissospermine
Description
geissospermine: cholinesterase Inhibitor from the bark extract of Brazilian Geissospermum vellosii; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
geissospermine : A indole alkaloid comprising two indole-derived polycyclic moieties joined by a cyclic ether linkage. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|
| Geissospermum | genus | [no description available] | Apocynaceae | The dogbane family of the order Gentianales. Members of the family have milky, often poisonous juice, smooth-margined leaves, and flowers in clusters.[MeSH] |
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 5281401 |
| CHEBI ID | 27776 |
| SCHEMBL ID | 7571616 |
| MeSH ID | M0561005 |
Synonyms (7)
| Synonym |
|---|
| C09200 |
| geissospermine |
| CHEBI:27776 |
| methyl (2r)-[(3ar,9s,11as,11bs,12s,13as,14s)-14-ethyl-2,3,11a,12,13,13a-hexahydro-11h,11bh-1,12-ethano[1,3]oxazino[3,4,5-lm]pyrrolo[2,3-d]carbazol-9-yl][(2r,3e,12bs)-3-ethylidene-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizin-2-yl]acetate |
| SCHEMBL7571616 |
| methyl (2r)-2-[(2r,3e,12bs)-3-ethylidene-2,4,6,7,12,12b-hexahydro-1h-indolo[2,3-a]quinolizin-2-yl]-2-[(1r,9s,12s,13s,14s,19s,21s)-14-ethyl-10-oxa-8,16-diazahexacyclo[11.5.2.11,8.02,7.016,19.012,21]henicosa-2,4,6-trien-9-yl]acetate |
| Q27103324 |
Roles (1)
| Role | Description |
|---|
| EC 3.1.1.7 (acetylcholinesterase) inhibitor | An EC 3.1.1.* (carboxylic ester hydrolase) inhibitor that interferes with the action of enzyme acetylcholinesterase (EC 3.1.1.7), which helps breaking down of acetylcholine into choline and acetic acid. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (4)
| Class | Description |
|---|
| indole alkaloid | An alkaloid containing an indole skeleton. |
| organic heterotetracyclic compound | |
| organic heteropentacyclic compound | |
| methyl ester | Any carboxylic ester resulting from the formal condensation of a carboxy group with methanol. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 3 (60.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 52.00
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 52.00 (24.57) | | Research Supply Index | 2.08 (2.92) | | Research Growth Index | 4.32 (4.65) | | Search Engine Demand Index | 79.51 (26.88) | | Search Engine Supply Index | 2.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |